Main content

    Lymphoma Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials

    Title: A Phase 1/2 single-arm, open-label study to evaluate the safety and efficacy of brentuximab vedotin in combination with bendamustine in patients with relapsed or refractory Hodgkin lymphoma (HL)
    Decscription: To assess the safety and tolerability of brentuximab vedotin in combination with bendamustine at the recommended dosing level
    Investigator: Caroline Behler, MD
    Eligibility: Subjects, 18 y/o and older, with documented histopathological diagnosis of classical HL excluding nodular lymphocyte predominant HL (NLPHL)
    Status: Active and open to enrollment
    Contact: Chrissy Raymundo, 415-600-3613, Email: RaymunCL@cpmcri.org about Study SGN35-016

    • updated June 2013

    Back to top